PANTUMOR 1479-0009

222730

ANV600-001

PRIMROSE (D9970C00001)

IMC-R117C-1004

SGNCEA5C-001

STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01- Positive Participants with Selected Advanced PIWIL1-Positive Cancers.



<ul class="wp-block-list">
<li>Code NKI: M23PIW</li>



<li>Code firm: IMC-R117C-1004</li>
</ul>



Principal Investigator



Dr. M. Vollebergh



Drugs 



IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein).



<h2 class="wp-block-heading">Summary</h2>



IMC-R117C is a PIWIL1 × CD3 Immune-mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC). This is a first-in-human trial designed to evaluate the safety and tolerability of IMC-R117C as a monotherapy and in combination, in participants with advanced PIWIL1-positive cancers.



Additional comments



Open for CRC